Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CGX1321
i
Other names:
CGX1321, CGX-1321, CGX 1321
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Curegenix
Drug class:
Wnt signalling pathway inhibitor, PORCN inhibitor
Related drugs:
‹
PRI724 (5)
WNT974 (2)
SM04690 (2)
BC2059 (2)
NCB-0846 (1)
XAV-939 (1)
OMP-18R5 (1)
CWP291 (0)
Circ0003039 (0)
E7386 (0)
KY1022 (0)
OMP-54F28 (0)
OTSA101-DTPA-90Y (0)
ETC-159 (0)
RXC004 (0)
PRI724 (5)
WNT974 (2)
SM04690 (2)
BC2059 (2)
NCB-0846 (1)
XAV-939 (1)
OMP-18R5 (1)
CWP291 (0)
Circ0003039 (0)
E7386 (0)
KY1022 (0)
OMP-54F28 (0)
OTSA101-DTPA-90Y (0)
ETC-159 (0)
RXC004 (0)
›
Associations
(1)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) (NCT02675946)
Phase 1b
Curegenix Inc.
Curegenix Inc.
Recruiting
Phase 1b
Curegenix Inc.
Recruiting
Last update posted :
01/26/2022
Initiation :
02/01/2016
Primary completion :
03/01/2023
Completion :
03/01/2023
BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3
|
BRAF V600E • BRAF V600
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login